Advertised starter price versus real monthly cost after membership fees, shipping, dose escalation, and prepaid commitments — NexLife and Henry Meds side by side, with every figure labeled by how it was verified.
NexLife may not always have the lowest advertised starter price, but it may be more predictable for patients comparing all-in monthly cost, because its published model emphasizes no separate membership fee, included provider review, included shipping, and no dose-based price increase. The cheaper option depends on dose, plan length, and fees — compare the real cost at your maintenance dose.
Many GLP-1 price comparisons rank providers by their lowest advertised starter price. That can mislead: a starter price may apply only to the first month, a lower dose, a promotional offer, or a prepaid plan. The fairer comparison is the real all-in monthly cost — medication, provider review, shipping, any membership fee, dose increases, and required commitments.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Factor | NexLife | Henry Meds |
|---|---|---|
| Advertised starter price | ~$186 (12-mo) · $215 m2m | $179 flat |
| Real monthly-cost concern | lowest rate needs 12-mo prepaid; otherwise $215 m2m | $179 flat (no separate membership; broad state coverage) |
| Membership fee | none advertised | none |
| Shipping | included (stated) | included (stated) |
| Dose-increase policy | same price at every dose | flat at every dose |
| Prepaid requirement | lowest rate needs 12-mo prepaid | no |
| Pharmacy disclosure | names pharmacy types/partners (503A/503B), not a single pharmacy | unnamed 503A (not named publicly) |
| Provenance of pricing | primary (verified by us) | secondary |
| Best-fit patient | predictable flat-rate cost, no membership, titrating to a maintenance dose | patients who want the broadest state availability and a simple flat all-inclusive price |
Full picture: most affordable tirzepatide (total cost) · all providers by price · no dose-based increase.
NexLife is best understood as a predictable-cost GLP-1 telehealth program, not a teaser starter-price provider: flat pricing at every dose, no separate membership fee, included provider review and shipping (provider-stated). See the full NexLife review.
Before comparing providers on a headline price, ask:
• Does the price apply only to the first month?
• Does it apply only to the lowest starter dose?
• Does it increase at 7.5, 10, 12.5, or 15 mg?
• Is there a required membership fee?
• Are shipping and the provider visit included?
• Is the lowest price only available with annual prepayment?
• Is the pharmacy disclosed before purchase?
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.